Use of the directional atherectomy for the treatment of femoro-popliteal lesions in patients with critical lower limb ischemia by Bracale, UMBERTO MARCELLO et al.
Translational Medicine @ UniSa - ISSN 2239-9747 2016, 15(6): 42-47 
 
 
42 
Università degli Studi di Salerno 
 
 Abstract - Femoro-popliteal PTA for the treatment 
of critical limb ischemia is frequently associated 
with unsatisfactory procedural success rates while 
directional atherectomy (DCA) has improved 
success rate since claudicant patients undergoing 
percutaneous treatment of femoro-popliteal 
obstructive disease. The aim of this prospective 
study is to evaluate the safety, efficacy and 
procedural success of DCA, at one year, in the 
percutaneous treatment of femoro-popliteal 
obstructive disease in patients with critical limb 
ischemia. 
Methods. From March 2012 to March 2013 18 
consecutive patients with critical limb ischemia were 
treated with DCA (Turbohawk/Covidien-ev3 
Endovascular Inc., North Plymouth, Minnesota, 
USA) for the treatment of femoro-popliteal 
obstructive disease. Patients were evaluated at 12 
months. 
Results. Technical and procedural success was 
achieved in every patient. No in-hospital major 
adverse cardiovascular events occurred. Primary 
endpoint: freedom from any amputation was 
obtained in all patients. Secondary endpoints: 
clinical (Rutherford class improvement) and 
hemodynamic success (Ankle-brachial index 
improvement) was achieved in all patients. 
Conclusion. The use of DCA for the treatment of 
femoro-popliteal obstructive disease is a safe and 
effective therapeutic strategy for patients with 
critical limb ischemia. The data included in our study 
should be considered hypothesis-generating in order 
to design of a randomized trial comparison with 
conventional PTA. 
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I.  INTRODUCTION 
 
 In developed countries of the western 
hemisphere, atherosclerotic critical limb ischemia (CLI) 
has an estimated incidence rate of at least 500 new cases 
per million habitants per year [1]. CLI revascularization is 
the mainstay of modern vascular therapy. Among non-
revascularized patients, 50% will undergo a major 
amputation one year after CLI onset. Perioperative 
mortality for above and below-the-knee amputation is 5-
10% and 15-20%, respectively [2]. Percutaneous 
transluminal angioplasty (PTA) is the first treatment 
option in CLI and femoro-politeal obstructive disease 
patients, particularly those with short arterial lesions. 
However such procedures often result in low acute 
success rates due to the difficulty of dilating fibrocalcific 
atherosclerotic plaque and, as a consequence, frequently 
require stent deployment [3,4]. Directional atherectomy 
(DCA) in claudicant patients has improved acute success 
rates by debulking the fibro-calcific portion of the 
atherosclerotic plaque thereby achieving proper lumen 
dilation and avoiding stent deployment (Rutherford 
Clinical Categories 2-3) [5]. 
The aim of this prospective study is to evaluate the safety 
and efficacy, at one year, of the directional atherectomy 
procedure and assess its impact on the procedural success 
of endovascular treatment for femoro-popliteal obstructive 
disease in patients with critical limb ischemia.  
 
 
II.  METHODS 
 
Patient population. From March 2012 to March 2013, 18 
consecutive patients with critical limb ischemia underwent 
DCA (TurboHawkTM plaque excision system, 
Covidien/ev3, Plymouth, MN) at two university hospital 
for treatment of femoro-popliteal obstructive disease. 
Patients were treated as standard in our practice and 
included in a prospective registry. Both the hospitals 
Ethics committee approved follow-up protocol. 
Inclusion criteria were: 
 clinical signs of critical limb ischemia: categories 
4-6 according to the Rutherford classification 
 superficial femoral artery (SFA) stenosis >50% 
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or popliteal artery stenosis (PA) >50% 
 lesion length < 30 cmat 1, 3, 6 and 12 months to 
evaluate occlusion or restenosis [5]. 
 reference vessel diameter > 4 mm 
 Duplex sonography (DUS) preoperative evidence 
of fibro/calcific lesion 
 
All patients were preoperatively evaluated with clinical 
examination, ABI measurement, Duplex scan and 
angiography, in order to define Rutherford Clinical Category 
(RCC), ecographic type of lesion and TASC category. 
 
Exclusion criteria were: 
 clinical sign of acute limb ischemia 
 in-stent restenosis 
 concomitant aneurysmatic disease 
 subintimal recanalization 
 
 
Concomitant therapy. All patients were given 
acetylsalicylic acid (ASA) (100 mg/day) and were 
instructed to take clopidogrel (75 mg/day) for at least 7 
days. Alternatively, patients received clopidogrel preload 
(300 mg) 24 hours before procedure. Post procedure, 
thyenopiridines were administered and continued for 30 
days and ASA was prescribed for life. For 
anticoagulation, 70-100 UI/Kg of un-fractioned heparin 
(UFH) was administered intravenously at the start of the 
procedure in accordance with our previously-described 
endovascular protocol [6]. Likewise, prevention of 
contrast-induced nephropathy (CIN) was careful 
monitored [7]. 
 
Procedure. All procedures were performed under local 
anaesthesia with the patient in a supine position. Vascular 
access was percutaneously achieved via the ipsilateral 
common femoral artery. In two cases a surgical cut-down 
was necessary, with a purse string suture positioning on 
the artery before the puncture; one due to the patient’s 
obesity (BMI 32 Kg/m2) and the other to treat an SFA 
ostial lesion. An 8 Fr sheath was advanced antegradely in 
all 18 patients’ SFA in order to achieve adequate support. 
Once diagnostic angiography was completed, a 0.014” 
guidewire was advanced into the distal popliteal artery. A 
filter for embolic protection (Spider FXTM embolic 
protection device (EPD), Covidien, Plymouth, MN) was 
positioned distal to the stenosis. Filter size was chosen 
according to landing artery diameter. DCA was performed 
using the Turbohawk™ device; a monorail exchange 
system running over a 0.014” guidewire which was 
chosen out of the 7 diameters and catheter lengths 
available to treat the femoral, popliteal and below the knee 
vessels. The device consists of a plaque blade cutter and 
reservoir at the tip, which stores the trimmed plaque. 
Under fluoroscopic guidance we advanced the device 
across the lesions at a speed of 1-2 mm per second with 
the cutting blade in constant orientation against the 
eccentric plaque, thereby avoiding circular movements. 
The cutting sequence was repeated as necessary in order 
to excise the largest amount of plaque possible (Fig. 1) 
(Fig. 2) (Fig. 3). Self-expanding nitinol stent implantation 
was permitted for bailout stenting (residual stenosis > 
30% or flow limiting dissections). Lesion pre-dilation was 
left at operator’s discretion. 
 
Post-procedural patient management. Access site 
haemostasis was achieved by manual compression in all 
percutaneous cases. Surgical access was closed gently 
pulling the purse string suture, after sheath removing, skin 
sutures completed the procedure. No vascular closure 
devices were used in this study. 
 
Patient Follow-up. Patients were evaluated at hospital 
discharge, at 30 days, and at 3, 6 and 12 months post 
procedure. Clinical follow-up was performed by clinical 
examination, ABI measurement and duplex 
ultrasonography scan. Repeat angiography was performed 
when proximal flow velocity ratio (PVR) was between 2.4 
to 5.0 (intermediate re-stenosis) and patient had clinical 
symptoms or PVR greater than 5.0 (severe re-stenosis), 
irregardless of clinical symptoms and in cases of vessel 
occlusion [8]. 
 
 
 
Fig. 1. Illustration of the Turbohawk™ device. A. Multiple preocclusive 
 SFA stenosis. B. Deployment of distal protection device. C. Plaque 
excision with Turbohawk™ (description of the technique in the text). 
 
Definitions. Technical success was defined as the ability 
to successfully perform DCA with a residual stenosis of 
<30%. Procedural success was defined as technical 
success without the occurrence of any major in-hospital 
adverse cardiovascular events (MACE). 
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Amputations distal to the metatarsal region were 
considered as limb salvage.  
Primary endpoint was limb salvage at one year. 
Secondary endpoints included: 
 primary patency at one year. 
 clinical success as defined by >1 category 
improvement in the RCC from baseline (or 2 
categories if pre- existing tissue loss) at one year. 
 hemodynamic success as defined by a 0.1 
improvement in the ABI during the period from 
baseline to 30 days post-procedure and no 
deterioration > 0.15 from the maximum early 
post procedure level at one year. 
 patency of below-the-knee artery as defined by 
freedom from obstructive lesions determining 
angiographic stenosis > 70%. 
 
Statistics. Nominal and categorical variables were 
presented as contingency tables with frequencies and 
percentages. Continuous variables were reported as the 
mean with standard deviation or median and interquartile 
ranges. Variables were compared by t test for normally 
distributed values (probability value <0.05 was considered 
statistically significant). 
 
 
 
Fig. 2. A. intraoperative image showing Turbohawk™ device and distal 
protection filter SpiderFX™. B. Long trimmed plaque. 
 
 
III.  RESULTS 
 
Out of the 18 patients included in the study, 12 (67%) 
were male. Demographic and clinical data are reported in 
Table I. Sixteen (88.9%) of the patients presented multiple 
SFA stenoses. In the remaining two cases a 
femoropopliteal artery occlusion was noted (11.1%). 
Mean length lesion was 12.3 cm. In 14 cases length was > 
10 cm. In 16 (88.9%) patients’ lesions were classified as 
TASC C. In the remaining two cases (11.1%) as TASC B. 
Lesion predilatation was necessary in seven (38.9%) 
cases, five of which were due to the presence of pre-
occlusive stenosis in the patients while the other two had 
total vessel occlusion. 
DCA was performed on all 18 patients with an ensuing 
technical success achieved in all cases (100%). No vessel 
perforation occurred. In no cases was bailout stent 
implantation necessary. Six (33.3%) diabetic patients with 
distal ulcers required additional tibial PTA in order to 
ensure direct blood flow to the foot. Procedural 
characteristics are summarized in Table II. Embolic 
material was evident at macroscopic inspection within the 
positioned filter in all of the cases (Fig. 4) thus 
demonstrating embolization of atherosclerotic debris. In 
only one case (5.6%) was the debris amount large enough 
to determine filter plugging. A normal antegrade flow was 
restored following filter recapture. No MACE occurred in 
hospital and, consequently, procedural success was also 
achieved in 100 % of the cases. No deaths or major 
amputations occurred during follow-up. Limb salvage was 
achieved in all patients while two cases required minor toe 
amputation. 
One-year duplex scan assessment revealed no recurrent 
stenosis or occlusions in 15 of the patients, giving a primary 
patency of 83.3%. In one of patients an SFA reocclusion 
occurred at 6 months however no signs of CLI recurrence 
were observed (Rutherford 3). Two other patients received 
femoro-popliteal below-the-knee bypass determining a 
secondary patency rate of 94.4% at 12 months. 
Preoperatively mean ABI was 0.35 ± 0.2. At one year ABI 
increased significantly to 0.60 ± 0.32 (P < .001). All patients 
had improved clinical status according to Rutherford 
classification (Baseline and follow up data to be inserted). 
Mean procedure time was 99 minutes (range 80-122; SD: 30) 
and mean fluoroscopy time was 29 minutes (range: 21-35; 
SD: 7.5). 
 
 
 
 
Fig. 3 Intraoperative angiogram. A. Superficial femoral and popliteal 
artery occlusion. B. Femoro-popliteal pre-dilatation.  C. Postprocedural 
result after plaque excision with Turbohawk. 
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Fig. 4. Macroscopic embolic material after distal embolic protection 
filter removal. 
 
IV.  DISCUSSION 
 
Nowadays the use of endovascular therapies as primary 
treatment in patients with CLI and femoro-popliteal 
lesions is on the rise. However the success of 
interventional endovascular therapy becomes hampered in 
the presence of calcific disease [9] while heavy 
calcification is a strong predictor for bailout stenting [10]. 
DCA improves acute success in claudicant patients by 
debulking the fibrocalcific portion of atherosclerotic 
plaque and achieving proper lumen dilation thereby 
avoiding stent deployment [5]. However initial results in 
patients with CLI and severely calcified femoro-popliteal 
vessels were unsatisfactory leading to stagnation in the 
clinical use of atherectomy [11]. Recent developments in 
atherectomy technology have renewed enthusiasm for the 
DCA technique. The TurboHawkTM plaque excision 
system, (Covidien/ev3, Plymouth, MN) was approved for 
clinical use by the FDA back in 2011 and represents an 
evolution in atherectomy therapy when compared to the 
widely employed and well-studied SilverHawkTM 
debulking device (Covidien/ev3, Plymouth, MN) system 
due to its thinner hub-based rotating blade situated behind 
a tapered, debris-collecting nose cone. The ‘TALON 
Registry’ described the first multicenter experience with 
the SilverHawk™ device on 601 patients with 1258 
symptomatic lower extremity atherosclerotic lesions (748 
limbs) and a reported technical success rate of 94.7%. At 
one year primary patency was reported in 81% of the 
cases. Out of the 1258 total, 245 were patients with CLI 
[12]. 
In a recently published single-center prospective study, 
the use of SilverHawk to treat calcified femoro-popliteal 
lesions achieved a very good peri-procedural success rate 
(92%) with minimal need for bailout stenting (8%) [13]. 
In the DEFINITIVE LE study 25% of the patients enrolled 
had CLI and bailout stenting was necessary in 4.1% of the 
cases, despite the presence of moderately or severely 
calcific lesions [14]. 
The use of DCA can be complicated by the occurrence of 
distal embolization. The value of using embolic protection 
with atherectomy is controversial and varies according to 
lesion characteristics and disease severity (i.e., CLI or 
single vessel run-off) [15]. As well, calcification has been 
shown to increase the risk of clinically significant 
embolism [16]. In the DEFINITIVE LE study, debris was 
present in 88.4% of distally placed filters upon recovery. 
Only three angiographically evident embolic events 
(2.3%) were reported, none of which resulted in clinical 
sequelae [17]. This embolization rate was comparable to 
stenting and PTA [18], notwithstanding the challenging 
calcified lesion population in the study. 
In our experience, attributed to a combined approach of 
distally protected DCA, procedural success was achieved 
in all the patients, resulting in a primary patency rate of 
94.4% at 12 months. Distal EPDs were placed in all 
patients and in 100% of the cases macroscopic 
atherosclerotic material was evident at filter removal. In 
one case the high amount of debris determined a ‘noflow’ 
image during intraoperative angiography. These findings 
demonstrate that embolization continues to be a concern 
for atherectomy devices suggesting the routinely use of 
distal EPDs with associated additional cost and procedural 
overload. Recently there is reasonable attention on the 
assumption of using DCA before drug-eluting balloon 
angioplasty considering that DCA removes plaque that 
may hamper the passage of the drugs to the vascular 
media. Preliminary experience in a small cohort of 
patients (60% were claudicants) demonstrated safety and 
efficacy of this combined treatment [19]. The vast 
majority of published data available on the use of DCA 
for femoro-popliteal intervention is based on the 
employment of the Silverhawk™ device. As was the case 
for Silverhawk™ when it was first employed and 
approved by FDA in 2007, an adequate learning curve is 
necessary to confidently master the use of the 
Turbohawk™ device [18,20,21]. We found that its main 
advantage is that it allows for more consistent plaque 
removal due to its technologically advanced design; an 
essential function given the large atherosclerotic burden of 
the CLI patients. 
 
 
 
TABLE I. DEMOGRAPHIC AND CLINICAL DATA 
 
N= 18 (%) 
_______________________________________________ 
Male                                                                       12 (66.7) 
Age, years (Median/IQ)                                   68.1 (56-83) 
Hypertension (%/N)                                                 16 (89) 
Hypercholesterolemia (%/N)                                   12 (67) 
Diabetes Mellitus (%/N)                                          14 (78) 
Smoking history (%/N)                                            12 (67) 
Chronic renal disease (%/N)                                       2 (11) 
Rutherford 4 (%/N)                                                    2 (11) 
Rutherford 5 (%/N)                                                    6 (33) 
Rutherford 6 (%/N)                                                  10 (56) 
CVD (%/N)                                                                 4 (22) 
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TABLE II. PROCEDURAL CHARACTERISTICS 
 
N = 18 (%) 
_______________________________________________ 
Pre-dilation                                                              7 (38.9) 
Distal protection                                                      18(100) 
Reference Vessel Diameter (mm) (Mean ± SD)    4.1 ± 1.2 
Lesion Length (mm) (Mean ± SD)                        123 ± 55 
Post-dilation                                                             3 (16.7) 
Bailout stenting (%)                                                      0 (0) 
Procedural success                                                  18 (100) 
 
 
 
V. CONCLUSIONS 
 
Our prospective study of 18 patients at a 12-month follow-
up has demonstrated that: 
 DCA can be safely performed to treat femoro-
popliteal obstructive disease in patients with CLI. 
 The use of DCA is associated with good clinical 
outcome and low recurrence rates. 
 The finding of macroscopic plaque debris in all 
patients is strong supporting evidence for the 
systematic use of the distal embolic protection 
device. 
Endovascular atherectomy with distal protection should be 
considered a treatment option for complex calcified 
disease in the lower extremities. Limitations of this study 
include lack of a control arm, a relatively small number of 
patients and long-term follow-up. 
This study was designed to include a specific cohort of 
patients and selection criteria could be considered in the 
design of an eventual, larger study. 
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